The idea of developing GLP‐1‐based therapies for type2 diabetes mellitus (T2DM) crystallised following the demonstration that overnight GLP‐1 infusion in people with T2DM raised insulin concentrations, suppressed glucagon release and normalised plasma glucose levels.2 The gene discussed is INS; the disease is type 2 diabetes mellitus.